Question by abbigail f: What would be a good treatment for people with dual diagnosis?
I’ve read that people with dual diagnosis must not just be treated for one of their illnesses, but rather for both. What is this treatment and how does it work?

Best answer:

Answer by aracely
The treatment is called effective integrated treatment. This treatment does not only involve treating mental illness, or substance abuse disorder. It involves treating both disorders simultaneously. The caregiver must be adept at handling people with co-occurring disorders, otherwise, treating only one might lead the other illness to come back. The treatment must involve trust between the patient and the caregiver. Assertive outreach, motivational interventions, counseling, and social support must also be present to prevent the patient from relapsing. This kind of treatment takes months, or even years to complete. This is because constant attention is needed to be given to the patient so as to prevent relapse.

Answer by brodrickbrand1972
THATS HALF WAY CORRECT,YOU HAVE TO FIRST ESTABLISH THE PROPER TREATMENT FOR ONE TO BE ABLE TO TREAT THE OTHER.IN MOST CASES YOU CAN TREAT BOTH ILLNESSES SIMULTAINOUSLY,IT TAKES TIME COMBINING THE MEDICATIONS,YOU FIRST HAVE TO DECIDE WHICH MEDICATIONS WORK PROPERLY,AND IF THE TWO DIFFERENT MEDICATIONS CAN BE COMBINED,WITH LITTLE OR NO E.S.P.(SIDE-EFFECTS.

Evidence Comes Up Short as Egypt Tries 3 Journalists
The three defendants — Peter Greste, an Australian; Mr. Fahmy, a dual citizen of Egypt and Canada; and Baher Mohamed, an Egyptian — have been held since their arrest in December on charges that they conspired with the Muslim Brotherhood to broadcast …
Read more on New York Times

Central State Hospital closings cause patient overflow at River Edge …
According to documents, they expanded services to provide for “additional individuals seeking outpatient services, residential long-term treatment for dual diagnosis, inpatient short-term psychiatric stabilization for adults, etc.” These expansions …
Read more on Colonnade (subscription)

BMS Study Shows Potential for New Hep C Treatment
Bristol-Myers Squibb Co. announced Phase 3 results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir (DCV), a NS5A inhibitor, and asunaprevir (ASV), a NS3 inhibitor, among genotype 1b …
Read more on Drug Discovery & Development

More Dual Diagnosis Treatment Information…